The University of Chicago Header Logo

Connection

Mark J. Ratain to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

This is a "connection" page, showing publications Mark J. Ratain has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
  1. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. Cancer Chemother Pharmacol. 1995; 36(3):204-10.
    View in: PubMed
    Score: 0.116
  2. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
    View in: PubMed
    Score: 0.072
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.